BioMarin Pharmaceutical
BMRN · Nasdaq · United States
Share price · BMRN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BMRN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026+5.0%
Nothing announced by BMRN that day or the session before.
- 3 Nov 2026-3.1%
- 22 Oct 2026+2.6%
Nothing announced by BMRN that day or the session before.
- 10 Aug 2026+7.9%
- 29 May 2026+8.6%
- 21 May 2026+7.8%
Nothing announced by BMRN that day or the session before.
- 5 May 2026-4.0%
- 19 Dec 2025+17.7%
Share of unusual movement by asset
For each asset, the share of BMRN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(10 total)
| Target & Modality | |||
|---|---|---|---|
Cerliponase alfa(BRINEURA) | Approved | Tripeptidyl peptidase 1 (TPP1) replacementProtein / enzyme therapeutic | Neuronal Ceroid Lipofuscinosis Type 2 |
Elosulfase alfa(VIMIZIM) | Approved | N-acetylgalactosamine-6-sulfatase (GALNS) replacementProtein / enzyme therapeutic | Mucopolysaccharidosis Type IVA |
Galsulfase(NAGLAZYME) | Approved | N-acetylgalactosamine 4-sulfatase (arylsulfatase B)Protein / enzyme therapeutic | Mucopolysaccharidosis Type VI |
Laronidase(ALDURAZYME) | Approved | Alpha-L-iduronidase (IDUA)Protein / enzyme therapeutic | Mucopolysaccharidosis Type I |
Migalastat(Galafold) | Approved | Alpha-galactosidase A (GLA / α-Gal A)Small molecule | Fabry Disease |
Pegvaliase(PALYNZIQ) | Approved | Phenylalanine ammonia lyase (enzyme substitution)Protein / enzyme therapeutic | Phenylketonuria |
| Approved | Phenylalanine hydroxylase (PAH)Small molecule | Phenylketonuria | |
Vosoritide(VOXZOGO) | Approved | Natriuretic peptide receptor B (NPR-B)Peptide | AchondroplasiaHypochondroplasia |
| Phase 2/3 | C-type natriuretic peptide (CNP) pathwayPeptide | Achondroplasia | |
| Phase 1/2 | DMD exon 51RNA / oligonucleotide | Duchenne Muscular Dystrophy |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (4)
April 2027 (1)
What to watch
2028 (1)
June 2028 (1)
What to watch
2029 (1)
2031 (2)
2038 (1)
May 2038 (1)
What to watch
2044 (1)
October 2044 (1)
What to watch
Regulatory and conference events
(8)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $1.0B | — | $736M+ $0 short-term inv. | $123M$188M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $990M | $207M | $874M+ $0 short-term inv. | —$168M operating cash flow | report ↗ |
| 2026-Q1 | $766M | $179M | $3.1B+ $0 short-term inv. | —$221M operating cash flow | report ↗ |
| 2025-Q3 | $776M | $409M | $1.3B+ $228M short-term inv. | $31M$369M operating cash flow | report ↗ |
| 2025-Q2 | $825M | $161M | $1.2B+ $218M short-term inv. | —$185M operating cash flow | report ↗ |
| 2025-Q1 | $745M | $159M | $1.0B+ $224M short-term inv. | —$174M operating cash flow | report ↗ |
| 2024-Q3 | $746M | $185M | $675M+ $255M short-term inv. | —$221M operating cash flow | report ↗ |
| 2024-Q2 | $712M | $184M | $972M+ $252M short-term inv. | —$119M operating cash flow | report ↗ |
| 2024-Q1 | $649M | $205M | $747M+ $300M short-term inv. | —$47M operating cash flow | report ↗ |
| 2023-Q3 | $581M | $191M | $785M+ $340M short-term inv. | —$136M operating cash flow | report ↗ |
| 2023-Q2 | $595M | $177M | $694M+ $477M short-term inv. | —$70M operating cash flow | report ↗ |
| 2023-Q1 | $596M | $172M | $580M+ $572M short-term inv. | —-$74M operating cash flow | report ↗ |
| 2022-Q3 | $505M | $158M | $762M+ $512M short-term inv. | $6.7M$158M operating cash flow | report ↗ |
| 2022-Q2 | $534M | $158M | $620M+ $490M short-term inv. | —$56M operating cash flow | report ↗ |
| 2022-Q1 | $519M | $161M | $605M+ $451M short-term inv. | —-$45M operating cash flow | report ↗ |
| 2021-Q3 | $409M | $158M | $617M+ $462M short-term inv. | $36M$97M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $3.2B | $922M | $1.3B+ $249M short-term inv. | —$828M operating cash flow | report ↗ |
For full-year 2025, BioMarin reported revenue of $3,221.25M, up 12.9% YoY, with R&D spend of $921.93M, up 23.4% YoY. The company recorded net income of $348.9M and held cash and equivalents of $1,311.68M at year-end.
BioMarin provided 2026 guidance for total revenues of $3,325M to $3,425M and Non-GAAP diluted EPS of $4.95 to $5.15, excluding any post-close contribution from its announced acquisition of Amicus Therapeutics, which is expected to close in Q2 2026. Key pipeline updates included positive Phase 1 PK data for BMN 333, a Phase 3 hypochondroplasia readout for VOXZOGO expected in 1H 2026, and a PDUFA date of February 28, 2026 for the PALYNZIQ adolescent label expansion. The company also decided to voluntarily withdraw ROCTAVIAN from the market after failing to identify a buyer.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $2.9B | $747M | $943M+ $195M short-term inv. | —$573M operating cash flow | report ↗ |
| 2023-FY | $2.4B | $747M | $755M+ $319M short-term inv. | —$159M operating cash flow | report ↗ |
| 2022-FY | $2.1B | $650M | $725M+ $567M short-term inv. | —$176M operating cash flow | report ↗ |
| 2021-FY | $1.8B | $629M | $587M+ $427M short-term inv. | $16M$305M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 6 sales ($4.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-18 | Friberg Gregory R · EVP, Chief R&D Officer | Open-market sale | 5,147 | $58.81 | $303K | Form 4 |
| 2026-09-30 | Friberg Gregory R · EVP, Chief R&D Officer | Tax withholding | 4,086 | $60.00 | $245K | Form 4 |
| 2026-09-10 | Plenge Robert M · director | Award / grant | 6,140 | — | — | Form 4 |
| 2026-09-02 | Davis George Eric · EVP, Chief Legal Officer | Open-market sale | 17,557 | $66.28 | $1.2M | Form 4 |
| 2026-06-02 | ANDERSON ELIZABETH M · director | Award / grant | 7,490 | — | — | Form 4 |
| 2026-06-02 | Bodem Barbara W. · director | Award / grant | 7,490 | — | — | Form 4 |
| 2026-06-02 | CLARK IAN T · director | Award / grant | 7,490 | — | — | Form 4 |
| 2026-06-02 | Dere Willard H · director | Award / grant | 7,490 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 550 reporting institutions held 183.6M shares ($10.1B, 94.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 19,818,301 | $1.1B |
| 2 | Dodge & Cox | 14,561,759 | $822.6M |
| 3 | PRIMECAP MANAGEMENT CO/CA/ | 14,194,005 | $801.8M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 8,643,164 | $488.3M |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 8,298,475 | $468.8M |
| 6 | AQR CAPITAL MANAGEMENT LLC | 7,676,541 | $429.3M |
| 7 | STATE STREET CORP | 7,295,079 | $412.1M |
| 8 | VIKING GLOBAL INVESTORS LP | 7,062,077 | $398.9M |
| 9 | CITADEL ADVISORS LLC | 4,512,634 | $254.9M |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 3,819,441 | $215.8M |
| 11 | DIMENSIONAL FUND ADVISORS LP | 3,802,930 | $214.8M |
| 12 | Vestal Point Capital, LP | 3,575,000 | $202.0M |
| 13 | FMR LLC | 3,567,031 | $201.5M |
| 14 | Capital Research Global Investors | 3,491,386 | $197.2M |
| 15 | MILLENNIUM MANAGEMENT LLC | 3,010,308 | $170.1M |